Vinay Prasad

Associate Professor

  • 2690 Citations
  • 26 h-Index
20092019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2009 2019

2019

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals

Herrera-Perez, D., Haslam, A., Crain, T., Gill, J., Livingston, C., Kaestner, V., Hayes, M., Morgan, D., Cifu, A. S. & Prasad, V., Jun 11 2019, In : eLife. 8

Research output: Contribution to journalArticle

Open Access
New England
American Medical Association
Medicine
Cardiovascular Diseases
Randomized Controlled Trials
1 Citation (Scopus)
Drug Approval
Quality Control
Randomized Controlled Trials
Standard of Care
Antineoplastic Agents
2 Citations (Scopus)
United States Food and Drug Administration
Biomarkers
Drug Approval
Pharmaceutical Preparations
Neoplasms

A reality check of the accelerated approval of immune-checkpoint inhibitors

Gill, J. & Prasad, V., Jan 1 2019, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

Open Access
Outcome Assessment (Health Care)
Neoplasms
Research Personnel
Cross-Sectional Studies
Clinical Trials
Conflict of Interest
Glioblastoma
Neoplasms
Equipment and Supplies
Registries

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda

Luo, J., Nishikawa, G. & Prasad, V., Sep 4 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 9, p. 2303-2311 9 p.

Research output: Contribution to journalReview article

Immunotherapy
Meta-Analysis
Monoclonal Antibodies
Neoplasms
Ligands
8 Citations (Scopus)

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

Haslam, A., Hey, S. P., Gill, J. & Prasad, V., Jan 1 2019, In : European Journal of Cancer. 106, p. 196-211 16 p.

Research output: Contribution to journalReview article

Meta-Analysis
Validation Studies
Biomarkers
Survival
Randomized Controlled Trials
1 Citation (Scopus)

Cancer screening: A modest proposal for prevention

Kim, M. S., Nishikawa, G. & Prasad, V., Mar 1 2019, In : Cleveland Clinic journal of medicine. 86, 3, p. 157-160 4 p.

Research output: Contribution to journalComment/debate

Open Access
Early Detection of Cancer

Case Reports in the Age of Twitter

Cifu, A. S., Vandross, A. L. & Prasad, V., Jan 1 2019, In : American Journal of Medicine.

Research output: Contribution to journalEditorial

Open Access

Confirmatory Trials for Drugs Approved on a Single Trial

Haslam, A. & Prasad, V., Jun 1 2019, In : Circulation. Cardiovascular quality and outcomes. 12, 6, p. e005494

Research output: Contribution to journalArticle

Valsartan
Drug Approval
Fish Oils
Pharmaceutical Preparations

Essere un medico conservativo

Mandrola, J., Cifu, A., Prasad, V. & Foy, A., Apr 1 2019, In : Recenti Progressi in Medicina. 110, 4, p. 156-158 3 p.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials

Chen, E. Y., Joshi, S. K., Tran, A. & Prasad, V., Jan 1 2019, In : JAMA Internal Medicine.

Research output: Contribution to journalArticle

Biomarkers
Clinical Trials
United States Food and Drug Administration
Drug Approval
Survival
9 Citations (Scopus)
Open Access
Immunotherapy
Pharmaceutical Preparations
Neoplasms
United States Food and Drug Administration
Melanoma

Improving the design of pivotal clinical trials

Prasad, V., Mar 1 2019, In : Clinical Advances in Hematology and Oncology. 17, 3, p. 150-152 3 p.

Research output: Contribution to journalArticle

Clinical Trials

Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?

Chapa, J., Haslam, A. & Prasad, V., Jun 1 2019, In : Mayo Clinic Proceedings. 94, 6, p. 951-956 6 p.

Research output: Contribution to journalShort survey

Open Access
Population Characteristics
Early Detection of Cancer

Making adjuvant therapy decisions with uncertain data

Gyawali, B. & Prasad, V., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 361-364 4 p.

Research output: Contribution to journalReview article

Open Access
Therapeutics
3 Citations (Scopus)

Metastasis-free survival in prostate cancer: Faster drug approvals, better drugs?

Parikh, R. B. & Prasad, V., Feb 1 2019, In : Journal of Clinical Oncology. 37, 4, p. 266-268 3 p.

Research output: Contribution to journalArticle

Drug Approval
Prostatic Neoplasms
Neoplasm Metastasis
Pharmaceutical Preparations

Real-world Evidence - What Does It Really Mean?

Nabhan, C., Klink, A. & Prasad, V., Jan 1 2019, In : JAMA Oncology.

Research output: Contribution to journalReview article

Registration studies — when should patients be deemed ineligible for aggressive therapy?

Cook, R. J., Gill, J. & Prasad, V., Jan 1 2019, In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

Therapeutics

Reply to C.J. Sweeney et al

Parikh, R. B. & Prasad, V., Jan 1 2019, In : Journal of Clinical Oncology. 37, 19, p. 1680-1681 2 p.

Research output: Contribution to journalLetter

Should Evidence Come with an Expiration Date?

Greene, P., Prasad, V. & Cifu, A., Jan 1 2019, In : Journal of general internal medicine.

Research output: Contribution to journalArticle

Testing for blinding in sham-controlled studies for procedural interventions: The third-party video method

Gill, J. & Prasad, V., Mar 11 2019, In : CMAJ. 191, 10, p. E272-E273

Research output: Contribution to journalComment/debate

Open Access
Latent Tuberculosis
Delivery of Health Care
1 Citation (Scopus)

The Case for Being a Medical Conservative

Mandrola, J., Cifu, A., Prasad, V. & Foy, A., Jan 1 2019, In : American Journal of Medicine.

Research output: Contribution to journalEditorial

Open Access
Evidence-Based Medicine
Clinical Decision-Making

Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs

Haslam, A., Crain, T., Gill, J., Herrera-Perez, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : American Journal of Medicine.

Research output: Contribution to journalArticle

Newspapers
Health Care Costs
PubMed
Delivery of Health Care
Publications
2018
1 Citation (Scopus)

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy - Reply

Hernandez, I., Prasad, V. & Gellad, W. F., Jan 1 2018, (Accepted/In press) In : JAMA oncology.

Research output: Contribution to journalArticle

T-Cell Antigen Receptor
Immunotherapy
Costs and Cost Analysis
5 Citations (Scopus)

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature

Nishikawa, G., Luo, J. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 143-151 9 p.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Neoplasms
History
Drug Therapy
Conflict of Interest

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Prasad, V., McCabe, C. & Mailankody, S., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Pharmaceutical Preparations
Costs and Cost Analysis
1 Citation (Scopus)

A pooled analysis of published, basket trials in cancer medicine

Hazim, A. & Prasad, V., Sep 1 2018, In : European Journal of Cancer. 101, p. 244-250 7 p.

Research output: Contribution to journalArticle

Medicine
Neoplasms
Fallopian Tube Neoplasms
Thymus Neoplasms
Seminoma
1 Citation (Scopus)

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Shanbhag, S. & Prasad, V., Nov 1 2018, In : European Journal of Cancer. 104, p. 252-253 2 p.

Research output: Contribution to journalLetter

Hodgkin Disease
Costs and Cost Analysis
cAC10-vcMMAE
21 Citations (Scopus)

Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

Prasad, V., Kaestner, V. & Mailankody, S., Feb 1 2018, In : JAMA oncology. 4, 2, p. 157-158 2 p.

Research output: Contribution to journalShort survey

DNA Mismatch Repair
Tumor Biomarkers
Pharmaceutical Preparations
Neoplasms
pembrolizumab
3 Citations (Scopus)

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

Tao, D. & Prasad, V., Sep 1 2018, In : The Lancet Oncology. 19, 9, p. 1150-1152 3 p.

Research output: Contribution to journalComment/debate

Medicine
Control Groups
Neoplasms
4 Citations (Scopus)

Concerns about the approval of nusinersen sodium by the US food and drug administration

Gerrity, M. S., Prasad, V. & Obley, A. J., Jun 1 2018, In : JAMA Internal Medicine. 178, 6, p. 743-744 2 p.

Research output: Contribution to journalComment/debate

United States Food and Drug Administration
Sodium
Cardiovascular Agents
Drug Therapy
Pharmaceutical Preparations
LCZ 696
1 Citation (Scopus)

Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply

Prasad, V., Jul 1 2018, In : JAMA Pediatrics. 172, 7, p. 701-702 2 p.

Research output: Contribution to journalLetter

Spinal Muscular Atrophy
Cost-Benefit Analysis
1 Citation (Scopus)

Crossover is not associated with faster trial accrual

Chen, E. Y. & Prasad, V., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 776-777 2 p., mdx821.

Research output: Contribution to journalLetter

3 Citations (Scopus)
Stroke
Myocardial Infarction
Clinical Trials
Neoplasm Metastasis
Recurrence
12 Citations (Scopus)

Direct-to-consumer genetic testing the implications of the US FDA's first marketing authorization for BRCA mutation testing

Gill, J., Obley, A. J. & Prasad, V., Jun 19 2018, In : JAMA - Journal of the American Medical Association. 319, 23, p. 2377-2378 2 p.

Research output: Contribution to journalReview article

Genetic Testing
Marketing
Mutation
Direct-To-Consumer Screening and Testing
LCZ 696

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Hilal, T. & Prasad, V., Jan 1 2018, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalArticle

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Biomarkers
Pharmaceutical Preparations
29 Citations (Scopus)

Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology

Marquart, J., Chen, E. Y. & Prasad, V., Aug 1 2018, In : JAMA oncology. 4, 8, p. 1093-1098 6 p.

Research output: Contribution to journalArticle

Genome
Neoplasms
United States Food and Drug Administration
Therapeutics
Pharmaceutical Preparations
4 Citations (Scopus)

Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings

Hayes, M. J. & Prasad, V., Mar 1 2018, In : Hastings Center Report. 48, 2, p. 10-13 4 p.

Research output: Contribution to journalArticle

Pharmacy and Therapeutics Committee
Conflict of Interest
conflict of interest
Advisory Committees
drug
6 Citations (Scopus)

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: Retrospective observational study

Wagner, J., Marquart, J., Ruby, J., Lammers, A., Mailankody, S., Kaestner, V. & Prasad, V., Jan 1 2018, In : BMJ (Online). 360, k668.

Research output: Contribution to journalArticle

United States Food and Drug Administration
Observational Studies
Retrospective Studies
Guidelines
Pharmaceutical Preparations
Simvastatin
Ezetimibe
7 Citations (Scopus)

Improving observational studies in the era of big data

Gill, J. & Prasad, V., Sep 1 2018, In : The Lancet. 392, 10149, p. 716-717 2 p.

Research output: Contribution to journalComment/debate

Observational Studies
1 Citation (Scopus)

Inconsistent reporting of potential conflicts of interest

Prasad, V., Jul 24 2018, In : JAMA - Journal of the American Medical Association. 320, 4, 1 p.

Research output: Contribution to journalLetter

Conflict of Interest

Inconsistent Reporting of Potential Conflicts of Interest

Prasad, V., Sep 1 2018, In : JAMA Pediatrics. 172, 9, 1 p.

Research output: Contribution to journalLetter

Conflict of Interest

Inconsistent Reporting of Potential Conflicts of Interest

Prasad, V., Oct 1 2018, In : JAMA Internal Medicine. 178, 10, p. 1424-1425 2 p.

Research output: Contribution to journalLetter

Conflict of Interest
1 Citation (Scopus)

Inconsistent Reporting of Potential Conflicts of Interest

Prasad, V., Oct 1 2018, In : JAMA oncology. 4, 10, 1 p.

Research output: Contribution to journalLetter

Conflict of Interest